In support of this hypothesis, Mariani et al. (2018) reported that patients at high risk for FSGS progression (cluster 3 patients) are characterized by a transcriptional profile consistent with TNF activation that correlates with eGFR loss [21]. This evidence concerns the gene TNF and focal segmental glomerulosclerosis.